OneAscent Family Office LLC purchased a new position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) in the 4th quarter, HoldingsChannel.com reports. The institutional investor purchased 3,491 shares of the company’s stock, valued at approximately $613,000.
Several other hedge funds have also recently added to or reduced their stakes in AZN. Brighton Jones LLC lifted its stake in Astrazeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock worth $379,000 after purchasing an additional 2,789 shares during the last quarter. AQR Capital Management LLC lifted its stake in Astrazeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares during the last quarter. Amundi lifted its stake in Astrazeneca by 54.4% during the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares during the last quarter. Jump Financial LLC lifted its stake in Astrazeneca by 898.4% during the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after purchasing an additional 30,125 shares during the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in Astrazeneca by 1.2% during the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after purchasing an additional 559 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on AZN shares. Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Wednesday, May 13th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Weiss Ratings began coverage on Astrazeneca in a research note on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Thursday, May 21st. Finally, Sanford C. Bernstein reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Astrazeneca has an average rating of “Moderate Buy” and a consensus target price of $205.33.
Astrazeneca Trading Up 2.3%
NYSE AZN opened at $186.06 on Friday. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71. The company has a current ratio of 0.91, a quick ratio of 0.71 and a debt-to-equity ratio of 0.52. The stock has a 50-day moving average of $190.84 and a 200-day moving average of $184.91. The firm has a market cap of $288.57 billion, a PE ratio of 27.94, a price-to-earnings-growth ratio of 1.56 and a beta of 0.25.
Astrazeneca (NYSE:AZN – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.The company had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. As a group, sell-side analysts forecast that Astrazeneca Plc will post 9.52 EPS for the current year.
Astrazeneca Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
